Grants per year
Grants
Active
Assessing the Transcriptional Response to Triple CFTR modulator Treatment of the Nasal Epithelium
1/1/20 → 12/31/21
Project: Research project
Prot #MRT5005-101: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 (CO-hCFTR mRNA/ICE LNP) Administered by Nebulization to
Rho, Inc., Translate Bio, Inc.
12/7/18 → 12/7/21
Project: Research project
Prot #PTI-428-06: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects with Cystic Fibrosis
MS Clinical Services, LLC, Proteostasis Therapeutics, Inc.
10/29/18 → 10/29/21
Project: Research project
Sexual and Reproductive Health in Adult Women with Cystic Fibrosis
University of Pittsburgh, Cystic Fibrosis Foundation
10/1/18 → 9/30/20
Project: Research project
Prot #VX17-445-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Greenphire, Inc., Vertex Pharmaceuticals Incorporated
7/29/18 → 7/29/21
Project: Research project
Prot #VX17-445-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
Greenphire, Inc., Vertex Pharmaceuticals Incorporated
7/10/18 → 7/10/21
Project: Research project
Prot #VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/M
Greenphire, Inc., Vertex Pharmaceuticals Incorporated
6/5/18 → 6/5/21
Project: Research project
Prot #PTI-801-01: A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, an
Rho, Inc., Proteostasis Therapeutics, Inc.
9/26/17 → 9/26/20
Project: Research project
TEACH Trial: Testing the Effect of Adding Chronic Azithromycin to Inhaled Tobramycin. A randomized, placebo-controlled, double-blinded trial of azithromycin 500 mg thrice weekly in combination with inhaled tobramycin
Seattle Children's, Cystic Fibrosis Foundation Therapeutics, Inc.
1/1/16 → 11/30/20
Project: Research project
Fixed Price Subproject for "TEACH Trial: Testing the Effect of Adding Chronic Azithromycin to Inhaled Tobramycin. A randomized, placebo-controlled, double-blinded trial of azithromycin 500 mg thrice weekly in combination with inhaled tobramycin"
Seattle Children's, Cystic Fibrosis Foundation Therapeutics, Inc.
1/1/16 → 11/30/20
Project: Research project
Prot #VX14-661-110: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F50
Jain, M., Lam, A. P. & Prickett, M.
Quintiles, Inc., Vertex Pharmaceuticals Incorporated
10/12/15 → 10/12/21
Project: Research project
Therapeutics Development Center
Cystic Fibrosis Foundation Therapeutics, Inc.
1/1/14 → 3/31/21
Project: Research project